Professor Junlong Zhuang: Interim Analysis Results of the PROact Study Further Support Combined Therapy for mHSPC Patients with HRR Gene Mutations

Professor Junlong Zhuang: Interim Analysis Results of the PROact Study Further Support Combined Therapy for mHSPC Patients with HRR Gene Mutations

2024.06.16
Studies have found that metastatic hormone-sensitive prostate cancer (mHSPC) patients with homologous recombination repair (HRR) gene mutations progress to metastatic castration-resistant prostate cancer (mCRPC) more quickly, significantly affecting overall survival. Previous research has shown that the combination of olaparib with abiraterone and prednisone significantly improves survival in mCRPC patients. At this year's ASCO Annual Meeting, a study from Professor Hongqian Guo's team at Nanjing Drum Tower Hospital analyzed this combined treatment strategy for mHSPC patients with HRR mutations for the first time. "Oncology Frontier" invited Professor Junlong Zhuang from Nanjing Drum Tower Hospital to share the findings on-site.
Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum

Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum

2024.06.16
Richter's transformation (RT), a complication of chronic lymphocytic leukemia (CLL), poses significant diagnostic and therapeutic challenges. At the "2024 Nanjing Lymphoma Forum," Professor Lei Fan from Jiangsu Provincial People's Hospital delivered an academic report titled "Research Progress in Richter's Transformation," covering the latest advancements in its definition, characteristics, molecular mechanisms, and treatment progress. Hematology Frontier had the privilege of interviewing Professor Fan, discussing the significance of the Nanjing Lymphoma Forum and his outlook on the diagnosis and treatment of Richter's transformation.
ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

2024.06.15
The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) was grandly held in Chicago, USA, from May 31 to June 4, 2024. As a premier global event, ASCO gathers oncology experts from around the world to discuss the latest advancements and future trends in the field. At this year's ASCO conference, several studies led by Professor Pei Dong from the Sun Yat-sen University Cancer Prevention and Treatment Center were selected, making a significant impact on the international stage. These studies not only represent new progress in the field of urologic oncology in China but also contribute to the global development of urologic oncology. "Oncology Frontier" has summarized these studies for our readers.
Expert Commentary | Professor Lin Zhang: Efficacy and Safety of 90Y Resin Microsphere Radiation Segmentectomy for Hepatocellular Carcinoma

Expert Commentary | Professor Lin Zhang: Efficacy and Safety of 90Y Resin Microsphere Radiation Segmentectomy for Hepatocellular Carcinoma

2024.06.15
Traditionally, radiation dosage for yttrium-90 (90Y) resin microsphere radiation segmentectomy (RS) was determined using body surface area or partition models, which often resulted in lower prescription activities. Recent studies have used the Medical Internal Radiation Dosimetry (MIRD) formula to determine radiation doses, providing higher tumor absorption doses. A recent retrospective study published in Radiology by Beth Israel Deaconess Medical Center, Harvard Medical School, demonstrated that hepatocellular carcinoma (HCC) patients receiving 90Y resin microsphere RS achieved high tumor absorption doses and sustained tumor remission with good safety profiles. International Hepatology invited Professor Lin Zhang from the Tsinghua University Affiliated Beijing Tsinghua Chang Gung Hospital Hepato-Pancreato-Biliary Interventional Center to introduce and comment on this study.
ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients

ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients

2024.06.15
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, Eastern Time. One study on OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy, garnered widespread attention. This research focuses on patients with immune checkpoint inhibitor (ICI)-resistant metastatic melanoma. Unlike traditional TIL therapy, OBX-115 has a key advantage: it does not require high-dose interleukin-2 (IL-2) systemic treatment, reducing the toxicity risk for patients. Initial results indicate that OBX-115 performs well in both safety and efficacy, providing new hope for ICI-resistant melanoma patients.
ASCO 2024 | Advances in Uveal Melanoma Treatment

ASCO 2024 | Advances in Uveal Melanoma Treatment

2024.06.15
Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.
Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

2024.06.15
Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.
ASCO 2024丨Professor Zengjun Li: SHR-A1912 Phase I Study Results First Unveiled, Pioneering a New Chapter in B-NHL Treatment

ASCO 2024丨Professor Zengjun Li: SHR-A1912 Phase I Study Results First Unveiled, Pioneering a New Chapter in B-NHL Treatment

2024.06.15
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held in Chicago from May 31 to June 4. At this conference, Chinese researchers presented the first results of the Phase I study of SHR-A1912 in patients with B-cell non-Hodgkin lymphoma (B-NHL) on the international stage, including preliminary key data from the dose-escalation (D-ESC) and dose-expansion (D-EXP) phases. To promote the standardization of lymphoma diagnosis and treatment in China, Hematology Frontier invited the principal investigator of this study, Professor Zengjun Li from Shandong Cancer Hospital, to deeply analyze the study’s highlights and discuss future trends in the field of lymphoma treatment.
Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)

Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)

2024.06.15
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, USA, from May 31 to June 4. The ASCO Annual Meeting gathers oncology experts, doctors, and researchers from around the world to share the latest research findings, discuss cutting-edge diagnostic and therapeutic techniques, and advance the field of oncology. A study by Professor Jianxiang Wang and Professor Ying Wang's team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, was selected for an oral presentation (Abstract 6505) at the conference. The study explores the therapeutic application of the CD3×CD19 bispecific antibody CN201 in relapsed/refractory adult acute B-cell lymphoblastic leukemia (R/R B-ALL), showing promising treatment prospects. "Oncology Frontier - Hematology Frontier" invited Professor Ying Wang for an interview to discuss this study and the treatment of R/R B-ALL.
ASCO & EHA Special丨Professor Jun Zhu: Opportunities and Challenges for Chinese Original Anticancer Drugs on the International Stage

ASCO & EHA Special丨Professor Jun Zhu: Opportunities and Challenges for Chinese Original Anticancer Drugs on the International Stage

2024.06.15
As summer begins, the sun shines warmly and everything thrives. In this vibrant season, two major international events in the pharmaceutical world—the American Society of Clinical Oncology (ASCO 2024) and the European Hematology Association (EHA 2024) annual meetings—are about to take place. These meetings are not only platforms for showcasing global pharmaceutical innovations but also important venues for domestic and international oncology and hematology experts to exchange ideas and spark insights. On the eve of these events, Oncology Frontier - Hematology Frontier invited Professor Jun Zhu from Peking University Cancer Hospital to discuss "Chinese Original Drugs on the International Stage: Opportunities and Challenges." Under Professor Zhu's guidance, we will review the achievements of Chinese anticancer drugs in lymphoma treatment, examine the gaps with international standards, and look ahead to future developments. Through continuous learning, innovation, and international cooperation, Chinese anticancer drug research and development (R&D) will reach new heights, bringing hope to cancer patients and contributing to the dream of a Healthy China with Chinese wisdom and strength.